Se­quoia Chi­na leads $37M in­fu­sion in­to ra­dio­phar­ma­ceu­ti­cals play­er set­ting up shop in Chi­na and Bel­gium

It’s not just Amer­i­can star­tups that are tun­ing in­to the ris­ing in­ter­est in ra­dio­phar­ma­ceu­ti­cals.

Se­quoia Chi­na is lead­ing a $37 mil­lion Se­ries A in­to Full-Life Tech­nolo­gies, a biotech head­quar­tered in Shang­hai with of­fices in Brus­sels, Bel­gium, to de­vel­op a pipeline of ra­dioac­tive can­cer ther­a­pies.

The idea isn’t new: As clin­i­cians start­ed rou­tine­ly de­ploy­ing ra­di­a­tion to kill can­cer cells, sci­en­tists and drug­mak­ers have long been ex­plor­ing ways to lim­it that pow­er­ful ef­fect on­ly to can­cer cells while spar­ing healthy cells. But re­cent progress in the pro­duc­tion of ra­dioiso­topes — cou­pled with big in­vest­ments from Big Phar­ma, most no­tably No­var­tis and Bay­er — has in­spired a new wave of star­tups.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER